Translational research is a key component of understanding and treating medical challenges. By working across the spectrum, from small animals to human subjects, this area of research transforms laboratory observations into actual treatments for individuals and the public.
Increasing the viability of donor lungs for transplantOne of the biggest challenges facing organ transplantation is keeping donor organs healthy. Our Comprehensive Transplant Center is the first in Ohio to offer a process that uses a mechanical system to respirate, warm, nourish and repair donor lungs outside the body, thus improving the odds that they can be used for transplant. Bryan Whitson, MD, PhD and principal investigator in the COPPER Laboratory, is one of the pioneers of this process at Ohio State. The COPPER laboratory is a multidisciplinary collaboration dedicated to expanding the science of endothelial cell repair in ischemia reperfusion and exploiting ex vivo perfusion to assess, repair and modify donor allografts.
Working to protect preemies from a deadly diseaseNecrotizing enterocolitis (NEC) is a devastating disease that affects the intestines of premature babies, causing infection, inflammation and destruction of the intestinal wall. And it’s become the leading cause of death in neonatal intensive care units across the country. Despite more than six decades of research, the morbidity and mortality rates of the disease remain unchanged, at up to 50 percent. The Besner Laboratory focuses on the discovery of novel therapeutic strategies to protect infants’ intestines from NEC and help them thrive and grow.
Treating disease at the cellular levelIn an excessive response to stimulation such as injury, some vascular cells change phenotype, deviating from their normal functions. These ill-behaved cells deform the vessel wall, leading to obstruction of blood flow and, ultimately, cardiovascular disease. Dr. Lian-Wang Guo’s research has centered on both sigma-1 receptors and BET proteins, and how they impact the changes in vascular cells. Encouraged by promising outcomes, researchers in the Guo lab are collaborating with bioengineers to develop innovative drug delivery strategies. Their goal is to translate their research into effective treatments for large populations, who might otherwise develop blindness or flow-obstructing vascular diseases.
Influencing immune system reactions for long-term transplantation successTransplant surgeon Ginny Bumgardner, MD, PhD, conducts transplant immunology research, motivated by the power of transplantation to transform the lives of patients with end-stage organ failure. She and her collaborators investigate novel approaches to manipulate immune system reactions after transplantation of cells and organs to prevent rejection and promote long-term transplant function.
Treating disease with genome editing technologiesUnderstanding how genetic defects lead to human diseases (including muscular dystrophy) is just one part of Dr. Renzhi Han’s research. The other part is harder: how to correct those genetic flaws in the genome. Dr. Han’s laboratory is addressing these questions through the use of genetic animal models and leading-edge genome editing technologies to develop novel therapeutic strategies to treat them.
Researching the molecular mechanisms of both heart and skeletal musclesHeart and skeletal muscles have a unique ultrastructure to ensure their primary contractile function. Dr. Hua Zhu’s laboratory is interested in the cellular and molecular mechanisms that maintain the structural properties of striated muscle for their normal physiology. The long-term goal of Dr. Zhu’s lab is to translate their discoveries in basic science into treatment of human diseases caused by structural and functional alterations of striated muscle. These diseases include ischemic heart diseases, muscular dystrophy and sarcopenia.
Increasing transplants with better assessment and repair of donor organsWith the increasing success of organ transplantation, there is a disparity between the number of organs available for transplantation and recipients on the waiting list. To expand the donor pool, extended criteria and marginal donor organs have been used with increased frequency. Unfortunately, these donor organs may not function as well and can increase the risk of complications to the recipient. Dr. Sylvester Black’s laboratory is addressing the assessment and repair of these organs using technologies such as normothermic ex-vivo perfusion and cellular repair molecules. The goal is to expand the donor pool and use these organs with increased safety for transplant patients.
Exploring bioengineered tissue to save infants with congenital heart defectsChristopher Breuer, MD, is the principal investigator on the first FDA-approved study evaluating the use of tissue engineered vascular grafts in congenital heart surgery in humans. His work is both basic and applied in nature. Dr. Breuer’s basic science research is centered on investigating the cellular and molecular mechanisms underlying neotissue formation in cardiovascular tissue-engineered constructs.
Working with Dr. Toshiharu Shinoka, he was the first in the world to tissue engineer blood vessels and implant them in human infants.